ArticleTranslational andrology and urology2025
Machine learning-based screening of potential diagnostic markers for prostate cancer with immune cell infiltration analysis and experimental validation.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate adenocarcinoma (PRAD) poses a significant global health burden. Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3C (APOBEC3C) exhibits context-dependent roles in cancer but its function in PRAD remains unclear. This study aims to resolve APOBEC3C's functional duality in PRAD and identify immune-related hub genes using integrated bioinformatics and experimental validation. Methods: Screening of PRAD differentially expressed genes (DEGs), Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and CIBERSORT immune infiltration assessment were performed based on The Cancer Genome Atlas (TCGA) database. Second, key genes in DEGs were screened using random forest (RF) analysis, the least absolute shrinkage and selection operator (LASSO) regression model, and the Support Vector Machine-Recursive Feature Elimination (SVM-RFE). The diagnostic value of the characterized core gene was evaluated by receiver operating characteristic (ROC) curve analysis in both TCGA and external Gene Expression Omnibus (GEO)-GSE29079 cohorts. The correlation between the core gene and tumor-infiltrating immune cells was further analyzed. In addition, Results: DEG analysis identified 24,208 genes (2,269 up-regulated and 1,966 down-regulated). GO enrichment analysis showed that DEGs were mainly involved in biological processes such as regulation of vascular contraction, maintenance of epithelial homeostasis in the gastrointestinal tract, and intercellular adhesion; the KEGG pathway was enriched in vascular smooth muscle contraction, neuroactive ligand-receptor interactions, and cyclic adenosine monophosphate (cAMP) signaling pathways. Immune infiltration showed distinct distribution of 21 immune cells in PRAD Conclusions: This study revealed the regulatory role of APOBEC3C as an oncogene in PRAD progression, suggesting that it may become a potential molecular marker for PRAD diagnosis and targeted therapy and providing new ideas for clinical intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.